Shots:

• The P-IIb X-TOLE clinical trial evaluates the efficacy- safety- & tolerability of XEN1101 (25/20/10mg) vs PBO in 325 & 323 patients (in the safety & ITT population- respectively) with focal epilepsy
• The trial met its 1EPs i.e.- patients achieved a median reduction in monthly focal seizure frequency from baseline (52.8%/46.4%/33.2% vs 18.2%)- and other measures included a ≥50% reduction in monthly focal seizure frequency from baseline (54.5%/43.1/28.3 vs 14.9). The therapy was generally well-tolerated
• The therapy leads to treatment discontinuation due to AEs (15.8%/13.7%/ 2.2% vs 3.5)- higher incidence of TEAEs (85.1%/ 68.6%/ 67.4% vs 62.3)

  | Ref: Globe Newswire | Image: BioSpace